Difference between revisions of "Ziv-aflibercept (Zaltrap)"
Jump to navigation
Jump to search
m (updated diseases) |
m |
||
| Line 2: | Line 2: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Recombinant fusion protein between the Fc portion of human IgG1 and the extracellular domains of VEGF receptor 1 & 2 (VEGFR 1 & VEGFR 2), which binds VEGF-A and VEGF-B (vascular endothelial growth factor), as well as | + | Class/mechanism: Recombinant fusion protein between the Fc portion of human IgG1 and the extracellular domains of VEGF receptor 1 & 2 (VEGFR 1 & VEGFR 2), which binds VEGF-A and VEGF-B (vascular endothelial growth factor), as well as PGF (placental growth factor). By binding to and inhibiting these angiogenic growth factors, their neovascular activity, and vascular permeability, ziv-aflibercept inhibits tumor angiogenesis.<ref name="insert">[http://www.regeneron.com/zaltrap/zaltrap-fpi.pdf Ziv-aflibercept (Zaltrap) package insert]</ref><ref>[[Media:Zivaflibercept.pdf|Ziv-aflibercept (Zaltrap) package insert (locally hosted backup)]]</ref><ref>[http://www.regeneron.com/zaltrap/ Zaltrap manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| Line 10: | Line 10: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Colon cancer]] | *[[Colon cancer]] | ||
| + | *[[Rectal cancer]] | ||
==Clinical trials== | ==Clinical trials== | ||
| Line 18: | Line 19: | ||
*[http://www.uptodate.com/contents/aflibercept-patient-drug-information Aflibercept patient drug information (UpToDate)] -- note: this is for Eylea, not Zaltrap<ref>[http://www.uptodate.com/contents/aflibercept-patient-drug-information Aflibercept patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/aflibercept-patient-drug-information Aflibercept patient drug information (UpToDate)] -- note: this is for Eylea, not Zaltrap<ref>[http://www.uptodate.com/contents/aflibercept-patient-drug-information Aflibercept patient drug information (UpToDate)]</ref> | ||
| + | ==History of changes in FDA indication== | ||
| + | * 8/31/2012: Initial FDA approval "in combination with [[Fluorouracil (5FU) | 5-fluorouracil]], [[Folinic acid (Leucovorin) | leucovorin]], [[Irinotecan (Camptosar) | irinotecan]] - ([[Colon_cancer#FOLFIRI_.26_Ziv-aflibercept_.28Zaltrap.29 | FOLFIRI]]), is indicated for patients with [[Colon_cancer#Advanced_or_metastatic_disease | metastatic colorectal cancer (mCRC)]] that is resistant to or has progressed following an [[Oxaliplatin (Eloxatin) | oxaliplatin]]-containing regimen." | ||
| + | |||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Kinase inhibitors]] | ||
| + | [[Category:PGF inhibitors]] | ||
| + | [[Category:VEGF inhibitors]] | ||
| + | |||
| + | [[Category:Colon cancer medications]] | ||
| + | [[Category:Rectal cancer medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 2012]] | ||
Revision as of 16:58, 6 November 2014
FDA approved 8/3/2012. Also known as aflibercept or VEGF trap. When used for macular degeneration, it is known as Eylea.
General information
Class/mechanism: Recombinant fusion protein between the Fc portion of human IgG1 and the extracellular domains of VEGF receptor 1 & 2 (VEGFR 1 & VEGFR 2), which binds VEGF-A and VEGF-B (vascular endothelial growth factor), as well as PGF (placental growth factor). By binding to and inhibiting these angiogenic growth factors, their neovascular activity, and vascular permeability, ziv-aflibercept inhibits tumor angiogenesis.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Clinical trials
- VELOUR, a Phase 3 Study of Aflibercept (A) Versus Placebo (pbo) in Combination with FOLFIRI for the Treatment of Patients (pt) with Previously Treated Metastatic Colorectal Cancer (MCRC)[4]
Patient drug information
- Brief patient counseling information is available on pages 16-17 of the package insert.[1]
- Aflibercept patient drug information (UpToDate) -- note: this is for Eylea, not Zaltrap[5]
History of changes in FDA indication
- 8/31/2012: Initial FDA approval "in combination with 5-fluorouracil, leucovorin, irinotecan - ( FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen."
References
- ↑ 1.0 1.1 1.2 Ziv-aflibercept (Zaltrap) package insert
- ↑ Ziv-aflibercept (Zaltrap) package insert (locally hosted backup)
- ↑ Zaltrap manufacturer's website
- ↑ J. Tabernero, E. Van Cutsem, R. Lakomy, J. Prausova, P. Ruff, G. Van Hazel, V. Moiseyenko, D. Ferry, J. McKendrick, K. Soussan-Lazard, E. Boelle, C. Allegra. VELOUR, a Phase 3 Study of Aflibercept (A) Versus Placebo (pbo) in Combination with FOLFIRI for the Treatment of Patients (pt) with Previously Treated Metastatic Colorectal Cancer (MCRC). 2011 European Multidisciplinary Congress. Abstract 6LBA. Presented September 25, 2011.
- ↑ Aflibercept patient drug information (UpToDate)